to chronic disease
Our AFFITOME® Technology
The basis for all AFFiRiS projects is the proprietary AFFITOME® technology. AFFITOPES® derived with the help of the AFFITOME® technology are short synthetic peptides that comprise not the target molecule itself or fragments thereof, but peptides with altered amino-acid sequences („molecular mimicry“). AFFITOPES® function as B-cell epitopes. The T-cell help required is provided by a carrier protein, which is covalently linked to the peptides. The aim of an AFFITOPE® vaccination is to induce an antibody response whereby the antibodies will bind specifically to a relevant appropriate target. The AFFITOME® technology provides several advantages as compared to competitors‘ approaches. There is a unique quality to our AFFITOME® active immunotherapy candidates as they are calibrated for specificity and selectivity of the immune response. This offers a level of safety and efficacy superior to native sequences. The AFFITOME® technology allows generation of intellectual property even in highly competitive environments.